Clinical Study Accrual Monitoring

Clinical studies are crucial to advancing science across the cancer care continuum, from prevention to survivorship. Broad inclusion of diverse people in clinical studies is essential to assuring that emerging cancer care standards for prevention, diagnosis and treatment are equally effective for all sectors of society.

Although federal mandates require sufficient representation of minorities in study samples, there continues to be nationwide disparity in the representation of racial and ethnic minorities and other groups in clinical studies. Factors that contribute to this disparity are well-documented and complex, including patient factors and broad community and societal factors.

Broad inclusion of diverse people in clinical studies is a priority of the Siteman Cancer Center. PECaD’s Clinical Study Accrual Monitoring/Clinical Studies Outreach (CSO) Program coordinates this effort. Investigators are highlighted in PECaD’s quarterly newsletter.

CSO Program Goals:

  • Increase minority recruitment through active interventions and monitoring.
  • Increase minority participation until participation rates mirror the incidence rates for individual cancers.
  • Equalize Siteman patient demographics with those of the service region.

To learn more, e-mail or call 314-747-4611.


Resources for Clinical Investigators

When submitting protocols for review, all Siteman Cancer Center investigators are required to identify target patient accrual by gender, race and ethnicity. For treatment and ancillary studies, investigators are advised to use the Incidence Cancer Cases by Disease Site tables. For prevention and screening studies, they are advised to use population data for the primary catchment area in the Demographic Information table.

For more information, click here or contact Jennifer Tappenden at